Vanta Bioscience IPO is about to debut on 25 September 2017, with an issue size of 7.56CR. Vanta Bioscience Ltd (VBL), established in 1995, is a contract research organization that specializes in providing safety assessment services. They cater to a wide range of industries including pharmaceuticals, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, and chemicals. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation.
VBL also offers risk assessment services to evaluate the safety of various products such as Active Pharmaceutical Ingredients (API), excipients, extractable and leachable, and pharmaceutical impurities resulting from manufacturing processes or product degradation. They also provide expert services to determine health-based exposure limits like permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers. With a strong focus on quality and innovation, VBL has established itself as a reliable partner for clients seeking preclinical contract research services.
Industry Overview
The Indian pharmaceutical industry is expected to grow at a rate of over 15% per annum between 2015 and 2020, making it one of the fastest-growing pharmaceutical markets in the world. By 2020, the industry is projected to reach a value of US$ 55 billion, becoming the sixth-largest pharmaceutical market globally. Branded generics currently dominate the Indian pharmaceutical market, accounting for nearly 80% of the market share in terms of revenues.
Furthermore, India has maintained its edge over China in pharmaceutical exports, with a year-on-year growth rate of 11.44% to US$ 12.91 billion in FY 2015-16. The country’s pharmaceutical exports are also expected to continue growing at a rate of 8-10% in FY 2016-17. Meanwhile, imports of pharmaceutical products have seen a marginal increase of 0.80% year-on-year, reaching a value of US$ 1,641.15 million.
Vanta Bioscience IPO Details
| IPO Date | Sep 25, 2017 to Sep 27, 2017 |
| Listing Date | Oct 6, 2017 |
| Face Value | ₹10 per share |
| Price | ₹50 per share |
| Lot Size | 3000 Shares |
| Total Issue Size | 1,512,000 shares(aggregating up to ₹7.56 Cr) |
| Issue Type | Fixed Price Issue IPO |
| Listing At | BSE SME |
Objects of the Issue
The objects of the Net Proceeds of the Issue are:
1. Augmenting additional working capital requirements;
2. General Corporate Purposes.
Vanta Bioscience IPO Prospectus
Company Contact Information
Vanta Bioscience Ltd
NO 02/G/308/G, NO 3/FF/SF/1-20-248 Umajay Complex,
Rasoolpura, Secunderabad,
Hyderabad � 500 003
Phone: +91 40 6657 5454
Email: info@vantabio.com
Website: http://www.vantabio.com
Vanta Bioscience IPO Registrar
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://www.bigshareonline.com/
Vanta Bioscience IPO Lead Manager(s)
- Inventure Merchant Banker Services Pvt Ltd (Past IPO Performance)
, established in 1995, is a contract research organization that specializes in providing safety assessment services){kind=link}